[144] Wingstop Inc SEC Filing

Filing Impact

(Low)

Filing Sentiment

(Neutral)

Form Type

144

Rhea-AI Filing Summary

On 29 Jul 2025, Standard BioTools Inc. (LAB) filed an 8-K disclosing new executive retention incentives.

CEO Michael Egholm is granted 3,000,000 RSUs: 25 % vests 1 Aug 2026; the remaining 75 % vests in three equal annual tranches thereafter, subject to continuous service.
CFO Alex Kim is granted 1,500,000 RSUs: 40 % vests 20 Jul 2026 and 60 % vests 20 Jul 2027.
Grants are issued under the amended 2011 Equity Incentive Plan and governed by the 2023/2024 Change-of-Control & Severance Plans.
The Human Capital Committee also raised Mr. Kim鈥檚 annual cash bonus target to 80 % of base salary, retroactive to 1 Jan 2025.

No operating or financial results accompanied the filing. While the equity awards strengthen leadership retention, they add share-based compensation expense and create potential dilution for existing shareholders.

Positive

Strengthened leadership retention via multi-year RSU schedules for CEO and CFO.
Improved alignment of executives with shareholder interests through sizable equity stakes.

Negative

Potential dilution of roughly 5-6 % if all RSUs vest and are issued.
Higher compensation expense without attached performance metrics may raise governance questions.

Insights

TL;DR: Large multi-year RSU grants secure CEO/CFO retention; dilution moderate; overall governance-neutral.

The combined 4.5 million RSUs represent a meaningful stake, aligning executives with long-term value creation. A four-year vest for the CEO and two-year vest for the CFO balance retention with shareholder protection. Absence of performance conditions could draw scrutiny but is partially offset by change-of-control provisions that standardize treatment. Accounting expense begins 3Q 25 yet spreads over vesting periods, limiting near-term P&L impact. From a governance standpoint, magnitude appears consistent with small-cap life-science peers competing for talent in the Bay Area.

TL;DR: Neutral event鈥攈elps keep leadership, but dilution risk offsets benefit.

At current share count (~80 M), the grants equal roughly 5.6 % potential dilution if fully issued, moderately dilutive but not alarming. Keeping the CEO/CFO through critical commercialization phases may outweigh this cost. Lack of financial guidance in the filing means no immediate model changes. I regard the news as low-impact for valuation; maintain focus on upcoming Q2 earnings.

08/01/2025 - 04:21 PM

144: Filer Information

Filer CIK

Filer CCC

Is this a LIVE or TEST Filing?

LIVE TEST

Submission Contact Information

Name

Phone

E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold

Name and Address of the Broker

Number of Shares or Other Units To Be Sold

Aggregate Market Value

Number of Shares or Other Units Outstanding

Approximate Date of Sale

Name the Securities Exchange

Common

Morgan Stanley Smith Barney LLC Executive Financial Services
1 New York Plaza
8th Floor
New York NY 10004

5400

2030887.77

27923753

08/01/2025

NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class

Date you Acquired

Nature of Acquisition Transaction

Name of Person from Whom Acquired

Is this a Gift?

Date Donor Acquired

Amount of Securities Acquired

Date of Payment

Nature of Payment *

Common

08/01/2025

Stock Option Exercise

ISSUER

719

08/01/2025

Cash

Common

06/11/2020

Restricted Stock

ISSUER

2095

06/11/2020

Not Applicable

Common

12/24/2020

Employee Stock Purchase Plan

ISSUER

716

12/24/2020

Cash

Common

02/17/2020

Performance Shares

ISSUER

1870

02/17/2020

Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Source:

AG真人官方